X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ST266 is a cell-free sterile biologic solution containing hundreds of proteins and other factors at physiologic levels. Extensive preclinical studies have shown that ST266’s multiple components result in a variety of anti-inflammatory and neuroprotective responses.
Lead Product(s): ST266
Therapeutic Area: Gastroenterology Product Name: ST266
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
ST266 is an investigational treatment for severe systemic inflammation, known as a cytokine storm, and ultimately sepsis, which is frequently associated with infectious diseases such as COVID-19.
Lead Product(s): ST266
Therapeutic Area: Immunology Product Name: ST266
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
ST266 is a cell-free biologic containing hundreds of proteins and other factors involved in cellular healing, neuroprotection, and modulation of inflammation. Agreement furthers study of intranasal delivery of ST266 for ophthalmology and brain-related conditions.
Lead Product(s): ST266
Therapeutic Area: Ophthalmology Product Name: ST266
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: SipNose
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 01, 2021
Details:
The TBI models will utilize targeted intranasal nose-to-brain administration of ST266. The ultimate goals are to advance ST266 into human clinical trials of targeted intranasal administration for TBI.
Lead Product(s): ST266
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ST266
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Walter Reed Army Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 01, 2021
Details:
The studies demonstrated that the complete ST266 secretome is required to obtain the full neuroprotective and myelin-protective effects in the experimental autoimmune encephalomyelitis (EAE) mouse model of optic neuritis.
Lead Product(s): ST266
Therapeutic Area: Immunology Product Name: ST266
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021
Details:
Dr. Brown will discuss the development of Noveome’s neuroprotective program which is evaluating intranasal “nose-to-brain” delivery of its novel platform biologic, ST266, to treat traumatic brain injury and optic nerve/retinal diseases and injuries.
Lead Product(s): ST266
Therapeutic Area: Ophthalmology Product Name: ST266
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
New, peer-reviewed results demonstrate, for the first time, the neuroprotective properties of systemically delivered AMP cells in mice with experimental autoimmune encephalomyelitis (EAE)-induced experimental optic neuritis (ON) and myelitis.
Lead Product(s): ST266
Therapeutic Area: Ophthalmology Product Name: ST266
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Results suggest that ST266 is consistent with pre-clinical studies in which ST266 treatment was associated with reduced inflammation, decreased neutrophil infiltration, and increased re-epithelization in a rabbit model for corneal incision and abrasion.
Lead Product(s): ST266
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Under the terms of the collaboration, Singota will manufacture Noveome’s ST266 to be used for IV infusion in Phase I and II clinical trials.
Lead Product(s): ST266
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Singota Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 12, 2020
Details:
Funding enables existing clinical trial of its lead product candidate, ST266, to proceed as company joins global response with covid-19 program.
Lead Product(s): ST266
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Commonwealth of Pennsylvania
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
